Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Atypical Presentation of Ewing's Sarcoma with a Single Left Orbital Metastasis.

Polish journal of radiology

Puglia M, Acquaviva A, Ponsiglione A, Barbuto L, Di Paolo N, De Rosa D, Sicuranza S, Maurea S, Imbriaco M.
PMID: 26568777
Pol J Radiol. 2015 Oct 25;80:483-5. doi: 10.12659/PJR.894507. eCollection 2015.

BACKGROUND: We present an uncommon case of Ewing's sarcoma in a 16-year-old boy.CASE REPORT: This case can be considered unique because of the atypical presentation, normal laboratory tests and absence of the typical symptoms such as pain, masses or...

Cite
Puglia M, Acquaviva A, Ponsiglione A, et al. Atypical Presentation of Ewing's Sarcoma with a Single Left Orbital Metastasis. Pol J Radiol. 2015;80:483-5doi: 10.12659/PJR.894507.
Puglia, M., Acquaviva, A., Ponsiglione, A., Barbuto, L., Di Paolo, N., De Rosa, D., Sicuranza, S., Maurea, S., & Imbriaco, M. (2015). Atypical Presentation of Ewing's Sarcoma with a Single Left Orbital Metastasis. Polish journal of radiology, 80483-5. https://doi.org/10.12659/PJR.894507
Puglia, Marta, et al. "Atypical Presentation of Ewing's Sarcoma with a Single Left Orbital Metastasis." Polish journal of radiology vol. 80 (2015): 483-5. doi: https://doi.org/10.12659/PJR.894507
Puglia M, Acquaviva A, Ponsiglione A, Barbuto L, Di Paolo N, De Rosa D, Sicuranza S, Maurea S, Imbriaco M. Atypical Presentation of Ewing's Sarcoma with a Single Left Orbital Metastasis. Pol J Radiol. 2015 Oct 25;80:483-5. doi: 10.12659/PJR.894507. eCollection 2015. PMID: 26568777; PMCID: PMC4625620.
Copy Download .nbib Format: NLM
A novel approach to teaching placement of a B-lynch suture: description of technique and validation of teaching model.

Journal of graduate medical education

Vetere PF, Wayock CP, Muscat J, Sicuranza G.
PMID: 23997884
J Grad Med Educ. 2012 Sep;4(3):367-9. doi: 10.4300/JGME-D-11-00186.1.

INTRODUCTION: Postpartum hemorrhage is a major cause of maternal morbidity and mortality throughout the world and uterine atony is the leading cause of postpartum hemorrhage. The B-Lynch brace suture is a fertility-sparing approach to treating intractable uterine atony at...

Cite
Vetere PF, Wayock CP, Muscat J, et al. A novel approach to teaching placement of a B-lynch suture: description of technique and validation of teaching model. J Grad Med Educ. 2012;4(3):367-9doi: 10.4300/JGME-D-11-00186.1.
Vetere, P. F., Wayock, C. P., Muscat, J., & Sicuranza, G. (2012). A novel approach to teaching placement of a B-lynch suture: description of technique and validation of teaching model. Journal of graduate medical education, 4(3), 367-9. https://doi.org/10.4300/JGME-D-11-00186.1
Vetere, Patrick F, et al. "A novel approach to teaching placement of a B-lynch suture: description of technique and validation of teaching model." Journal of graduate medical education vol. 4,3 (2012): 367-9. doi: https://doi.org/10.4300/JGME-D-11-00186.1
Vetere PF, Wayock CP, Muscat J, Sicuranza G. A novel approach to teaching placement of a B-lynch suture: description of technique and validation of teaching model. J Grad Med Educ. 2012 Sep;4(3):367-9. doi: 10.4300/JGME-D-11-00186.1. PMID: 23997884; PMCID: PMC3444193.
Copy Download .nbib Format: NLM
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia.

Clinical case reports

Zappone E, Cencini E, Defina M, Sicuranza A, Gozzetti A, Ciofini S, Raspadori D, Mecacci B, Bocchia M.
PMID: 33088538
Clin Case Rep. 2020 Jul 07;8(10):2000-2002. doi: 10.1002/ccr3.3041. eCollection 2020 Oct.

A case of an early-relapsed high-risk T-ALL with high BCL-2 expression on leukemic blasts was successfully treated with decitabine and venetoclax, achieving a CR. We suggest decitabine and venetoclax should be synergistic in BCL2-positive ALL.

Cite
Zappone E, Cencini E, Defina M, et al. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep. 2020;8(10):2000-2002doi: 10.1002/ccr3.3041.
Zappone, E., Cencini, E., Defina, M., Sicuranza, A., Gozzetti, A., Ciofini, S., Raspadori, D., Mecacci, B., & Bocchia, M. (2020). Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clinical case reports, 8(10), 2000-2002. https://doi.org/10.1002/ccr3.3041
Zappone, Elisabetta, et al. "Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia." Clinical case reports vol. 8,10 (2020): 2000-2002. doi: https://doi.org/10.1002/ccr3.3041
Zappone E, Cencini E, Defina M, Sicuranza A, Gozzetti A, Ciofini S, Raspadori D, Mecacci B, Bocchia M. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep. 2020 Jul 07;8(10):2000-2002. doi: 10.1002/ccr3.3041. eCollection 2020 Oct. PMID: 33088538; PMCID: PMC7562845.
Copy Download .nbib Format: NLM
The Role of Tumor-Associated Macrophages in Hematologic Malignancies.

Cancers

Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M.
PMID: 34298810
Cancers (Basel). 2021 Jul 18;13(14). doi: 10.3390/cancers13143597.

The tumor microenvironment includes dendritic cells, T-cytotoxic, T-helper, reactive B-lymphoid cells and macrophages; these reactive cells could interplay with malignant cells and promote tumor growth and survival. Among its cellular components, tumor-associated macrophages (TAM) represent a component of the...

Cite
Cencini E, Fabbri A, Sicuranza A, et al. The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143597.
Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., & Bocchia, M. (2021). The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers, 13(14), . https://doi.org/10.3390/cancers13143597
Cencini, Emanuele, et al. "The Role of Tumor-Associated Macrophages in Hematologic Malignancies." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143597
Cencini E, Fabbri A, Sicuranza A, Gozzetti A, Bocchia M. The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers (Basel). 2021 Jul 18;13(14). doi: 10.3390/cancers13143597. PMID: 34298810; PMCID: PMC8304632.
Copy Download .nbib Format: NLM
Acute lung injury complicating blood transfusion in post-partum hemorrhage: incidence and risk factors.

Mediterranean journal of hematology and infectious diseases

Teofili L, Bianchi M, Zanfini BA, Catarci S, Sicuranza R, Spartano S, Zini G, Draisci G.
PMID: 25408855
Mediterr J Hematol Infect Dis. 2014 Oct 22;6(1):e2014069. doi: 10.4084/MJHID.2014.069. eCollection 2014.

BACKGROUND: We retrospectively investigated the incidence and risk factors for transfusion-related acute lung injury (TRALI) among patients transfused for post-partum hemorrhage (PPH).METHODS: We identified a series of 71 consecutive patients with PPH requiring the urgent transfusion of three or...

Cite
Teofili L, Bianchi M, Zanfini BA, et al. Acute lung injury complicating blood transfusion in post-partum hemorrhage: incidence and risk factors. Mediterr J Hematol Infect Dis. 2014;6(1):e2014069doi: 10.4084/MJHID.2014.069.
Teofili, L., Bianchi, M., Zanfini, B. A., Catarci, S., Sicuranza, R., Spartano, S., Zini, G., & Draisci, G. (2014). Acute lung injury complicating blood transfusion in post-partum hemorrhage: incidence and risk factors. Mediterranean journal of hematology and infectious diseases, 6(1), e2014069. https://doi.org/10.4084/MJHID.2014.069
Teofili, Luciana, et al. "Acute lung injury complicating blood transfusion in post-partum hemorrhage: incidence and risk factors." Mediterranean journal of hematology and infectious diseases vol. 6,1 (2014): e2014069. doi: https://doi.org/10.4084/MJHID.2014.069
Teofili L, Bianchi M, Zanfini BA, Catarci S, Sicuranza R, Spartano S, Zini G, Draisci G. Acute lung injury complicating blood transfusion in post-partum hemorrhage: incidence and risk factors. Mediterr J Hematol Infect Dis. 2014 Oct 22;6(1):e2014069. doi: 10.4084/MJHID.2014.069. eCollection 2014. PMID: 25408855; PMCID: PMC4235434.
Copy Download .nbib Format: NLM
Residual Peripheral Blood CD26.

Frontiers in oncology

Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D.
PMID: 29900128
Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018.

Chronic myeloid leukemia (CML) patients in sustained "deep molecular response" may stop TKI treatment without disease recurrence; however, half of them lose molecular response shortly after TKI withdrawing. Well-defined eligibility criteria to predict a safe discontinuation up-front are still...

Cite
Bocchia M, Sicuranza A, Abruzzese E, et al. Residual Peripheral Blood CD26. Front Oncol. 2018;8:194doi: 10.3389/fonc.2018.00194.
Bocchia, M., Sicuranza, A., Abruzzese, E., Iurlo, A., Sirianni, S., Gozzini, A., Galimberti, S., Aprile, L., Martino, B., Pregno, P., Sorà, F., Alunni, G., Fava, C., Castagnetti, F., Puccetti, L., Breccia, M., Cattaneo, D., Defina, M., Mulas, O., Baratè, C., Caocci, G., Sica, S., Gozzetti, A., Luciano, L., Crugnola, M., Annunziata, M., Tiribelli, M., Pacelli, P., Ferrigno, I., Usala, E., Sgherza, N., Rosti, G., Bosi, A., & Raspadori, D. (2018). Residual Peripheral Blood CD26. Frontiers in oncology, 8194. https://doi.org/10.3389/fonc.2018.00194
Bocchia, Monica, et al. "Residual Peripheral Blood CD26." Frontiers in oncology vol. 8 (2018): 194. doi: https://doi.org/10.3389/fonc.2018.00194
Bocchia M, Sicuranza A, Abruzzese E, Iurlo A, Sirianni S, Gozzini A, Galimberti S, Aprile L, Martino B, Pregno P, Sorà F, Alunni G, Fava C, Castagnetti F, Puccetti L, Breccia M, Cattaneo D, Defina M, Mulas O, Baratè C, Caocci G, Sica S, Gozzetti A, Luciano L, Crugnola M, Annunziata M, Tiribelli M, Pacelli P, Ferrigno I, Usala E, Sgherza N, Rosti G, Bosi A, Raspadori D. Residual Peripheral Blood CD26. Front Oncol. 2018 May 30;8:194. doi: 10.3389/fonc.2018.00194. eCollection 2018. PMID: 29900128; PMCID: PMC5988870.
Copy Download .nbib Format: NLM
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of .

Cancers

Minetto P, Candoni A, Guolo F, Clavio M, Zannier ME, Miglino M, Dubbini MV, Carminati E, Sicuranza A, Ciofini S, Colombo N, Pugliese G, Marcolin R, Santoni A, Ballerini F, Lanino L, Cea M, Gobbi M, Bocchia M, Fanin R, Lemoli RM.
PMID: 33374216
Cancers (Basel). 2020 Dec 24;13(1). doi: 10.3390/cancers13010034.

The mutations of

Cite
Minetto P, Candoni A, Guolo F, et al. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of . Cancers (Basel). 2020;13(1)doi: 10.3390/cancers13010034.
Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M. E., Miglino, M., Dubbini, M. V., Carminati, E., Sicuranza, A., Ciofini, S., Colombo, N., Pugliese, G., Marcolin, R., Santoni, A., Ballerini, F., Lanino, L., Cea, M., Gobbi, M., Bocchia, M., Fanin, R., & Lemoli, R. M. (2020). Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of . Cancers, 13(1), . https://doi.org/10.3390/cancers13010034
Minetto, Paola, et al. "Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of ." Cancers vol. 13,1 (2020). doi: https://doi.org/10.3390/cancers13010034
Minetto P, Candoni A, Guolo F, Clavio M, Zannier ME, Miglino M, Dubbini MV, Carminati E, Sicuranza A, Ciofini S, Colombo N, Pugliese G, Marcolin R, Santoni A, Ballerini F, Lanino L, Cea M, Gobbi M, Bocchia M, Fanin R, Lemoli RM. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of . Cancers (Basel). 2020 Dec 24;13(1). doi: 10.3390/cancers13010034. PMID: 33374216; PMCID: PMC7796342.
Copy Download .nbib Format: NLM
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients.

Frontiers in oncology

Gozzetti A, Bacchiarri F, Sammartano V, Defina M, Sicuranza A, Mecacci B, Zappone E, Cencini E, Fabbri A, Raspadori D, Bocchia M.
PMID: 33415072
Front Oncol. 2020 Dec 21;10:570187. doi: 10.3389/fonc.2020.570187. eCollection 2020.

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy...

Cite
Gozzetti A, Bacchiarri F, Sammartano V, et al. Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. Front Oncol. 2020;10:570187doi: 10.3389/fonc.2020.570187.
Gozzetti, A., Bacchiarri, F., Sammartano, V., Defina, M., Sicuranza, A., Mecacci, B., Zappone, E., Cencini, E., Fabbri, A., Raspadori, D., & Bocchia, M. (2020). Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. Frontiers in oncology, 10570187. https://doi.org/10.3389/fonc.2020.570187
Gozzetti, Alessandro, et al. "Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients." Frontiers in oncology vol. 10 (2020): 570187. doi: https://doi.org/10.3389/fonc.2020.570187
Gozzetti A, Bacchiarri F, Sammartano V, Defina M, Sicuranza A, Mecacci B, Zappone E, Cencini E, Fabbri A, Raspadori D, Bocchia M. Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. Front Oncol. 2020 Dec 21;10:570187. doi: 10.3389/fonc.2020.570187. eCollection 2020. PMID: 33415072; PMCID: PMC7783633.
Copy Download .nbib Format: NLM
The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose.

Biomedicines

Fiorino F, Sicuranza A, Ciabattini A, Santoni A, Pastore G, Simoncelli M, Polvere J, Galimberti S, Auddino S, Baratè C, Montagnani F, Sammartano V, Bocchia M, Medaglini D.
PMID: 34680595
Biomedicines. 2021 Oct 15;9(10). doi: 10.3390/biomedicines9101480.

Immunization with mRNA SARS-CoV-2 vaccines has been highly recommended and prioritized in fragile subjects, including patients with myelofibrosis (MF). Available data on the vaccine immune response developed by MF patients and the impact of ruxolitinib treatment are still too...

Cite
Fiorino F, Sicuranza A, Ciabattini A, et al. The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines. 2021;9(10)doi: 10.3390/biomedicines9101480.
Fiorino, F., Sicuranza, A., Ciabattini, A., Santoni, A., Pastore, G., Simoncelli, M., Polvere, J., Galimberti, S., Auddino, S., Baratè, C., Montagnani, F., Sammartano, V., Bocchia, M., & Medaglini, D. (2021). The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines, 9(10), . https://doi.org/10.3390/biomedicines9101480
Fiorino, Fabio, et al. "The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose." Biomedicines vol. 9,10 (2021). doi: https://doi.org/10.3390/biomedicines9101480
Fiorino F, Sicuranza A, Ciabattini A, Santoni A, Pastore G, Simoncelli M, Polvere J, Galimberti S, Auddino S, Baratè C, Montagnani F, Sammartano V, Bocchia M, Medaglini D. The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. Biomedicines. 2021 Oct 15;9(10). doi: 10.3390/biomedicines9101480. PMID: 34680595; PMCID: PMC8533286.
Copy Download .nbib Format: NLM
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia.

Frontiers in oncology

Galimberti S, Grassi S, Baratè C, Guerrini F, Ciabatti E, Perutelli F, Ricci F, Del Genio G, Montali M, Barachini S, Giuliani C, Ferreri MI, Valetto A, Abruzzese E, Ippolito C, Iurlo A, Bocchia M, Sicuranza A, Martino B, Iovino L, Buda G, Salehzadeh S, Petrini M, Di Paolo A, Mattii L.
PMID: 30574454
Front Oncol. 2018 Dec 06;8:555. doi: 10.3389/fonc.2018.00555. eCollection 2018.

The Polycomb gene

Cite
Galimberti S, Grassi S, Baratè C, et al. The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Front Oncol. 2018;8:555doi: 10.3389/fonc.2018.00555.
Galimberti, S., Grassi, S., Baratè, C., Guerrini, F., Ciabatti, E., Perutelli, F., Ricci, F., Del Genio, G., Montali, M., Barachini, S., Giuliani, C., Ferreri, M. I., Valetto, A., Abruzzese, E., Ippolito, C., Iurlo, A., Bocchia, M., Sicuranza, A., Martino, B., Iovino, L., Buda, G., Salehzadeh, S., Petrini, M., Di Paolo, A., & Mattii, L. (2018). The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Frontiers in oncology, 8555. https://doi.org/10.3389/fonc.2018.00555
Galimberti, Sara, et al. "The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia." Frontiers in oncology vol. 8 (2018): 555. doi: https://doi.org/10.3389/fonc.2018.00555
Galimberti S, Grassi S, Baratè C, Guerrini F, Ciabatti E, Perutelli F, Ricci F, Del Genio G, Montali M, Barachini S, Giuliani C, Ferreri MI, Valetto A, Abruzzese E, Ippolito C, Iurlo A, Bocchia M, Sicuranza A, Martino B, Iovino L, Buda G, Salehzadeh S, Petrini M, Di Paolo A, Mattii L. The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. Front Oncol. 2018 Dec 06;8:555. doi: 10.3389/fonc.2018.00555. eCollection 2018. PMID: 30574454; PMCID: PMC6291509.
Copy Download .nbib Format: NLM
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization.

International journal of cardiology. Heart & vasculature

Correale M, Monaco I, Ferraretti A, Tricarico L, Sicuranza M, Gallotta AM, Formica ES, Acanfora G, Di Biase M, Brunetti ND.
PMID: 32346602
Int J Cardiol Heart Vasc. 2020 Apr 21;28:100513. doi: 10.1016/j.ijcha.2020.100513. eCollection 2020 Jun.

BACKGROUND: Several cardiopulmonary exercise test (CPET) parameters (peak VOAIM: To ascertain possible correlations between VP derived at CPET and hemodynamic parameters at right heart catheterization (RHC) indicative of PH.METHODS: Forty-seven consecutive outpatients with suspect of PAH were assessed by...

Cite
Correale M, Monaco I, Ferraretti A, et al. Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization. Int J Cardiol Heart Vasc. 2020;28:100513doi: 10.1016/j.ijcha.2020.100513.
Correale, M., Monaco, I., Ferraretti, A., Tricarico, L., Sicuranza, M., Gallotta, A. M., Formica, E. S., Acanfora, G., Di Biase, M., & Brunetti, N. D. (2020). Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization. International journal of cardiology. Heart & vasculature, 28100513. https://doi.org/10.1016/j.ijcha.2020.100513
Correale, Michele, et al. "Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization." International journal of cardiology. Heart & vasculature vol. 28 (2020): 100513. doi: https://doi.org/10.1016/j.ijcha.2020.100513
Correale M, Monaco I, Ferraretti A, Tricarico L, Sicuranza M, Gallotta AM, Formica ES, Acanfora G, Di Biase M, Brunetti ND. Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization. Int J Cardiol Heart Vasc. 2020 Apr 21;28:100513. doi: 10.1016/j.ijcha.2020.100513. eCollection 2020 Jun. PMID: 32346602; PMCID: PMC7178492.
Copy Download .nbib Format: NLM
Impact of cesarean delivery due to maternal choice on perinatal outcome in term nulliparous patients with a singleton fetus in a vertex presentation.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

Hoffmann E, Vintzileos WS, Akerman M, Vertichio R, Sicuranza GB, Vintzileos AM.
PMID: 33172330
J Matern Fetal Neonatal Med. 2020 Nov 10;1-6. doi: 10.1080/14767058.2020.1847078. Epub 2020 Nov 10.

OBJECTIVE: The objectives of our study were to: (1) evaluate the prevalence of cesarean delivery due to maternal request among nulliparous, term, singleton, vertex (NTSV) patients; (2) identify the clinical profile, if any, of these patients; and (3) compare...

Cite
Hoffmann E, Vintzileos WS, Akerman M, et al. Impact of cesarean delivery due to maternal choice on perinatal outcome in term nulliparous patients with a singleton fetus in a vertex presentation. J Matern Fetal Neonatal Med. 2020;1-6doi: 10.1080/14767058.2020.1847078.
Hoffmann, E., Vintzileos, W. S., Akerman, M., Vertichio, R., Sicuranza, G. B., & Vintzileos, A. M. (2020). Impact of cesarean delivery due to maternal choice on perinatal outcome in term nulliparous patients with a singleton fetus in a vertex presentation. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 1-6. https://doi.org/10.1080/14767058.2020.1847078
Hoffmann, Eva, et al. "Impact of cesarean delivery due to maternal choice on perinatal outcome in term nulliparous patients with a singleton fetus in a vertex presentation." The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians vol. (2020): 1-6. doi: https://doi.org/10.1080/14767058.2020.1847078
Hoffmann E, Vintzileos WS, Akerman M, Vertichio R, Sicuranza GB, Vintzileos AM. Impact of cesarean delivery due to maternal choice on perinatal outcome in term nulliparous patients with a singleton fetus in a vertex presentation. J Matern Fetal Neonatal Med. 2020 Nov 10;1-6. doi: 10.1080/14767058.2020.1847078. Epub 2020 Nov 10. PMID: 33172330.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries